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Epstein-Barr virus (EBV) 1 is a  herpes virus with a  very narrow tropism in that it 
can only infect humans and primates, and only the B lymphocytes of these susceptible 
species (1).  The virus will activate the host cell from a  state of rest to a  high rate of 
immunoglobulin (Ig) secretion (2) and, moreover, a proportion of the infected B cells 
have been shown  to proliferate indefinitely  in  vitro  (3).  This virus is  the causative 
agent  in  infectious  mononucleosis  (4),  and  it  has  strong  association  with  certain 
human B lymphocyte tumors (1). 
Of these  multiple  aspects of EBV,  we have focused on its capacity to induce  Ig 
secretion in resting B cells from human peripheral blood. Because EBV appears to be 
the only agent so far fully evaluated that can activate B  cells to Ig secretion in the 
absence of other cellular influences (5), we assume that it will be used as an analytical 
tool in assessing human B lymphocyte function in future clinical practice. The cellular 
mechanisms of the  activation  and  range of infectivity for B  lymphocytes therefore 
needs to be established. We also speculate that EBV will prove important in depicting 
the subcellular processes preceding and accompanying activation, because EBV can 
be  traced  intracellularly  by  virtue  of the  sequence  of antigens  it  generates.  The 
development of the  host-virus relationship  might  be correlated with  the  metabolic 
steps involved in moving the B cell from rest to a high rate of Ig secretion. 
In this communication, we demonstrate that there is a definite correlation between 
the induction of viral antigens, de novo synthesis of cellular DNA, and Ig secretion of 
in vitro EBV-infected B cells. Not all B cells are infectible by EBV, however, and a 
smaller fraction of the B cells can both be infected and activated to Ig secretion by 
EBV. 
Materials and Methods 
Cell Preparations.  Mononuclear leukocytes  were obtained from the blood of adult healthy 
donors.  They were separated from the buffy coat of citrate blood on Ficoll-Isopaque gradients 
(6). 
Purified Lymphocyte Populations.  These were of two kinds. First, T and B cells were fractionated 
by erythrocyte rosette separation. Lymphocytes binding sheep erythrocytes (SRBC) were spun 
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on a Ficoll gradient, and the layer not binding SRBC was recovered. These cells (B 1) contained 
<5% SRBC binding lymphocytes as judged by rerosetting, but contained >50% monocytes as 
judged by acridin orange staining (7). 
The extensively purified B cell preparation (B2)  was obtained by first clearing the Ficoll- 
separated cells from monocytes by exposing them to iron powder, followed by magnet treatment. 
Then the cells were passed through a nylon wool column and the retained cells were eluted by 
fetal bovine serum (FBS) at 37°C. The eluted fraction was rosetted with SRBC and spun over 
Ficoll-Isopaque to remove any remaining SRBC-binding T  cells. This yielded a cell suspension 
with <1% SRBC binding cells and no proliferative response to T  cell mitogens (8). 
Tissue Culture.  The cells were cultivated either in 2-ml round-bottomed tubes or 25-ml flasks 
in 5% CO2 in air. The RPMI 1640 medium was supplemented with either 10% heat-inactivated 
FBS or human AB serum and antibiotics (penicillin and gentamycin). 
Viral Exposure of Cells.  Two preparations of EBV were used,  i.e., the transforming virus 
obtained from the supernate of the B95-8 marmoset line (9) and the nontransforming variant 
from the supernate of the P3HR-1  Burkitt-derived line (10).  Both virus-containing supernates 
were filtered (0.45-/1 pore size) before use. 
Virus exposure was performed by suspending the cell pellets in virus-containing supernate 
and incubating this mixture for 60 min at 37°C at a concentration of 106 cells/ml. After this 
incubation, the cells were washed twice and cultivated in serum-supplemented RPMI  1640. 
When exposed to the T cell-dependent activator pokeweed mitogen (PWM) (Techtum, Ume~, 
Sweden), the cells were in continuous contact with the agent at a concentration of 20 ~g/ml. 
Measurement and Inhibition of DNA Synthesis.  Triplicate cultures of 200/~1  were cultured in 
microculture plates (3040;  Falcon Labware, Div. of Becton Dickinson & Co., Oxnard, Calif.). 
1/~Ci [aH]thymidine was added and the cells were incubated for an additional 6-12 h and then 
harvested in a microharvester. The dried filters were counted in a liquid scintillation counter. 
Inhibition of DNA synthesis was obtained by exposing the cells to cytosine arabinoside (Ara-C) 
(Sigma Chemical Co., St. Louis, Mo.) at 20 #g/ml for 36 h. 
Demonstration of EBV-determined Nuclear Antigen (EBNA ).  Methanol-acetone-fixed smears of 
cells were prepared and stained by anti-complement immunofluorescence (11) after exposure to 
an anti-EBNA-positive serum. 
Protein-A Plaque Assay.  This was performed as we have described previously (5). Protein-A- 
coupled erythrocytes were obtained by exposing one part washed and  packed SRBC to one 
part staphylococcal protein A (Pharmaeia Fine Chemicals, Uppsala, Sweden) at a concentration 
of 0.5 mg/ml in i0 parts CrCI~. Rabbit anti-human/l, y, and c~ antisera (Dako Ig, Copenhagen, 
Denmark), diluted 1:50, were used as developing sera. Guinea pig serum absorbed with equal 
volumes of packed SRBC for 1 h  at 4°C was the source of complement. Plaque-forming cells 
(PFC) are expressed as PFC/10  n cells initially cultured. 
Results 
Relationship  between Ig Production, De Novo DNA  Synthesis,  and Intracellular Presence of 
Viral  Antigens  in  B  Lymphocytes  Exposed  to  EBV.  Highly  purified  B  cells  (B2)  were 
exposed  to  dilutions  of  B95-8  supernate.  In  such  treated  cells,  the  proportion  of 
EBNA-positive cells was  assayed  after  2  and  6  d,  respectively, and  the  number  of 
IgM-producing B  cells was measured, as well as the level of DNA synthesis after 7 d 
of culture (Fig.  1). There is a  linear decrease of all these parameters as a  function of 
virus dilution. 
In  Fig.  2,  it is evident that  the induction of IgM-secreting cells falls linearly as a 
function of virus dilution in both purified (B 1) and nonpurified (B plus T) lymphocyte 
preparations. The purified B  cells, however, yield higher peak values and support a 
response with more dilute virus preparations. 
Role of De Novo DNA Synthesis and Transformation in the EBV-dependent  Induction of Ig 
Secretion.  We sought to establish the requirement for cell division in the activation of 
B  cells from  a  state  of rest  to  a  high  rate  of Ig secretion  by  performing  the  EBV 834  EPSTEIN-BARR VIRUS  ACTIVATION OF  B LYMPHOCYTES 
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FI~.  1.  Effect  of viral dilution on appearance of EBNA-containing cells on day 2 (O) and day 7 
('k); total IgM-secreting  cells (I), and DNA synthesis on day 7 (0) in extensively  purified B cells 
(B2). 
exposure of highly purified B lymphocytes (B2)  in the presence of Ara-C (12). Table 
I shows that cells that have been in contact with EBV (B95-8) for 7 d, but were in the 
presence of Ara-C for the last 36 h, show a  marked reduction of DNA synthesis and 
also generate fewer Ig-secreting cells than the controls without Ara-C (Table I). Ara- 
C was also added 36 h after virus exposure and the EBNA staining and determination 
of Ig-secreting cells was performed 36 h later, i.e., 3 d after starting the culture. No Ig- 
secreting cells were discernable in this experiment, although  13% of the cells stained 
for EBNA,  which  would  indicate  the proportion  of cells infectible by EBV  in  this 
preparation. In other preparations, where DNA synthesis was inhibited by Ara-C at 
this  early stage,  up  to  30%  of the purified  B  cells have been  infectible by EBV  as 
judged by EBNA positivity. 
An alternative approach for establishing the requirement for B cell transformation 
in  the  maturation  leading  to  active  Ig  secretion  was  to  expose  the  cells  to  the 
nontransforming variant of EBV, i.e., P3HR1.  This virus preparation failed  (Table 
II) to induce  Ig secretion,  as well as DNA synthesis  in human  B  cells,  but  it could 
specifically block these actions from subsequently added transforming EBV (B95-8). 
This effect of P3HR 1 is not the result of a  toxic or cytostatic action of the virus upon 
B cells in general,  because such treated cells can still be activated by PWM  (Table 
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(B1) cells (&), and unseparated peripheral blood lymphocytes (0). 
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TABLE  I 
Number of IgM, IgG, and IgA PFC, the Content of EBNA-positive Cells, and the Level of DNA Synthesis 
in Extensively Purified B Cells (B2) Exposed to EBV (B95-8) in the Presence or Absence of Ara-C, and 
Tested after 7 d in Culture 
DNA synthesis  Percent 
level of [aH]thy-  IgM PFC/106  IgA PFC/106  IgG PFC/106  EBNA-posi- 
Cell material  midine per 10  n  tive cells at 
cells*  day 7 
B2 cells alone  2,700  300  150  0  0 
B2 +  Ara-C:[:  2,750  0  50  50  0 
B2 +  EBV§  21,690  7,000  1,550  2,250  54 
B2 +  EBV +  Ara-C  650  2,000  100  900  36 
* DNA synthesis was measured by exposing the cells to 1 #Ci [aH]thymidine at the end of culture (day  7) 
and incubating for an additional  12 h. 
20 #g Ara-C was added 36 h before harvest at day 7. 
§ Cells were exposed  to the supernate of B95-8 line (106/ml)  for  1 h. Thereafter they were washed and 
cultivated in RPMI  1640 with 10% FBS in round tubes. 
Possible Role  of T  Cells  in  Stopping  the  Development of Ig-secreting Cells in  Short-Term 
Culture Stimulated by EB V.  In comparing  the EBV  responsiveness  of purified  (B 1)  vs. 
nonpurified  (B plus "1") B  cells, we also studied  the kinetics of response  measured  by 
the development of IgM-secreting cells. T  cell-deprived preparations  showed a  contin- 
uous  increase of cells producing  IgM,  as well as a  high proportion  of EBNA-positive 836  EPSTEIN-BARR  VIRUS  ACTIVATION OF  B  LYMPHOCYTES 
TABLE II 
Number of IgM and IgG PFC and DNA Synthesis in Cultures Exposed to 
Nontransforming EB V ( P3HR-1) vs.  Transforming EB V (B95-8) and the 
Inhibitory Effect of P3HR-1 on Polyclonal Ig Induction 
Material added 
PFC/106 cultured cells  DNA synthesis 
[aH]thymidine 
IgM  IgG  incorporation per 
culture at day 7 
B95-8"  6,400  3,760  6,950 
P3HR-I*  410  90  870 
PWM~  10,200  7,860  27,300 
P3HR-1 +  B95-8§  800  740  1,800 
B95-8 +  P3HR-1  4,040  2,950  4,710 
P3HR-1 +  PWM  10,830  9,430  18,660 
B95-8 +  PWM  t2,700  9,060  20,740 
0  60  0  640 
* Virus preparations were added by suspending 106 cells in  1 ml of virus supernates 
for 60 min at 37°C. After washes, the ceils were incubated in RPMI 1640 with 10% 
human AB serum. 
20/~g/ml of PWM added at day 0. 
§ Sequential addition of virus  was done by first  exposing the cells to one virus  as 
described above,  followed  by  washes,  and  then  to  the  second virus  supernate, 
followed by washes, after which the cells were put in culture. 
cells as late as  14 d  after initiating the culture  (Fig. 3), at a  time when cell mixtures 
containing  T  cells showed  very few Ig-secreting cells,  as  well  as  a  low  content  of 
EBNA-positive cells. 
Discussion 
We  have determined  by these  experiments  that  the  EBV-induced  activation  of 
human  B  lymphocytes  is  a  dose-dependent,  one-hit  phenomenon,  and  that  the 
maturational  step  involved  in  the  process  of  activation  requires  de  novo  DNA 
synthesis. 
Although  EBV receptors appear to be present  on virtually all B  cells,  as well as 
some null  cells  (13,  14),  only a  fraction  of these  B  cells  (10-30%)  appears  in  our 
experiments  to  be infectible  by  the  virus,  as judged  by the  appearance  of EBNA 
before DNA synthesis is initiated. We can say this provided that the concentration of 
virus is not the limiting factor. This does not appear to be the case, as we see a plateau 
effect with the lower viral dilutions (Fig. 2). However, using extensively concentrated 
virus, larger proportions of B cells (___90%) have on occasion been infected (15). We do 
not  know  what  characterizes  the  B  cells  to which  the  virus  can  gain  intracellular 
access, nor do we know what signifies the smaller fraction of the B cells (1-3%) that 
is driven to Ig secretion by the virus. We can perform the latter calculation because 
we know from our previous work that all Ig-producing cells in a cell culture exposed 
to EBV contain the EBNA antigen (2). 
It is well established that the EBV infection proceeds via the induction  of EBNA 
(10 h), and later, (40 h) of DNA synthesis (16). 
Differentiation from a rest state to active Ig synthesis in a B cell after EBV infection 
appears to be dependent on de novo DNA synthesis. This is true for all three major 
isotypes (Table I). The development of IgM-synthesizing cells appears somewhat less A. G. BIRD, S.  BRITTON,  I. ERNBERG, AND K. NILSSON 
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FIG. 3.  Effects  of T lymphocyte removal on the appearance of IgM-secreting  B lymphocytes  and 
EBNA-containing ceils as a function of time after virus exposure. (O), unseparated peripheral blood 
lymphoeytes; (A), T cell-depleted (B1) blood lymphoeytes.  The cell donor was immune to EBV as 
determined by anti-virus capsid antigen titers. 
sensitive  to  the  action  of Ara-C  than  to  IgG and  IgA.  This  is  in  agreement  with 
previously published information (17), which indicates that an immunological switch 
from IgM to IgG is strictly dependent of DNA synthesis, whereas the path from rest 
to active IgM secretion seems to be less so. In this system, we know that the virus is 
incorporated in cellular DNA and that viral proteins are synthesized, although DNA 
synthesis is blocked, but that a  high rate of Ig secretion is not initiated under those 
conditions.  Recently,  an  agent  has  been  described  that  can  induce  mainly  IgM 
synthesis in human B  cells without  the need for de novo DNA synthesis  (18).  EBV 
and formalin-killed Salmonella paratyphi thus differ in this regard. 
Nontransforming EBV, i.e., P3HR1, does not induce DNA synthesis or Ig formation 
in  human  B  cells  (Table  II).  Furthermore,  P3HR1  will  specifically  block the  Ig- 
inducing action of subsequently added transforming B95-8. This may suggest that the 
viruses  compete for similar membrane and/or  intraeellular  sites  in  the  same cells. 
Because the Ig-inducing action of PWM is not blocked, one must conclude that PWM 
either  activates different subsets of B  cells or uses different  pathways of activation 
(19). 
Finally,  T  cell-deprived B cell suspensions do not clear themselves of the EBNA- 
positive cells,  as  the  T  cell-containing  suspensions  do  (Fig.  3).  These data  support 
previously published evidence (20, 21) of T  cell regulation of EBV-infeeted B cells. 
Exact frequency analysis of responding cells will require limiting dilution analysis, 838  EPSTEIN-BARR VIRUS ACTIVATION OF B LYMPHOCYTES 
which  this  system  does  not  lend  itself to yet.  Thus,  we  have tried  to  find  out  the 
frequency of eternalizable cells by doing single cell transfer of EBNA-positive PFC to 
microwells with fibroblast feeder cells. One interpretation of these experiments is that 
either  these eternalizable  B  cells  are not  recruited  from the  high-rate Ig-producing 
cells or else they appear in low frequency (<1/50). 
Summary 
Epstein-Barr virus (EBV) will infect at least every third cell if exposed in vitro to 
an extensively purified B cell population from human peripheral blood. About  10% 
of such infected cells  will be driven into immunoglobulin synthesis and secretion, as 
judged by the indirect protein A plaque assay. The appearance of EB nuclear antigen, 
de novo DNA synthesis, and immunoglobulin secretion are linked phenomena accom- 
panying infection as judged by viral dilution experiments, which yield kinetics of a 
one-hit order. 
Induction of immunoglobulin secretion in B cells by EBV requires de novo synthesis 
of DNA, and consequently, nontransforming EBV (P3HR1)  will not induce immu- 
noglobulin secretion and will also specifically block such induction from subsequently 
added EBV. 
The  termination  of immunoglobulin  induction  by  EBV  in  short-term  cultures 
appears to be T  cell dependent. 
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